Understanding LI-RADS

Santillan, Cynthia; Tang, An; Cruite, Irene; Shah, Amol; Sirlin, Claude B.

doi:10.1016/j.mric.2014.04.007

Cited by 37 publications

(26 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRI was performed on a 1.5-Tesla scanner (Siemens Magnetom Avanto, Erlangen, Germany) using a phased array torso coil. The protocol included breath-hold unenhanced and contrast-enhanced (0.1 mmol/kg intravenous gadopentetate; Magnevist; Bayer, Wayne, NJ) T1-weighted three-dimensional fat-suppressed spoiled gradient-echo imaging (repetition time ms/ echo time ms, 5.77/2.77; field of view, 320–400 mm; matrix, 192 × 160; slice thickness, 2.5 mm; receiver bandwidth, 64 kHz; flip angle, 10°) in the hepatic arterial phase (20 s), portal venous phase (70 s) and delayed phase (3 min) [26, 27]. …”

Section: Methodsmentioning

confidence: 99%

Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver

et al. 2015

View full text Add to dashboard Cite

Objectives This study evaluated the predictive role of 1D, 2D and 3D quantitative, enhancement-based MRI regarding overall survival (OS) in patients with colorectal liver metastases (CLM) following intra-arterial therapies (IAT). Methods This retrospective analysis included 29 patients who underwent transarterial chemoembolization (TACE) or radioembolization and received MRI within 6 weeks after therapy. Tumour response was assessed using 1D and 2D criteria (such as European Association for the Study of the Liver guidelines [EASL] and modified Response Evaluation Criteria in Solid Tumors [mRECIST]). In addition, a segmentation-based 3D quantification of overall (volumetric [v] RECIST) and enhancing lesion volume (quantitative [q] EASL) was performed on portal venous phase MRI. Accordingly, patients were classified as responders (R) and non-responders (NR). Survival was evaluated using Kaplan–Meier analysis and compared using Cox proportional hazard ratios (HR). Results Only enhancement-based criteria identified patients as responders. EASL and mRECIST did not predict patient survival (P = 0.27 and P = 0.44, respectively). Using uni- and multivariate analysis, qEASL was identified as the sole predictor of patient survival (9.9 months for R, 6.9 months for NR; P = 0.038; HR 0.4). Conclusion The ability of qEASL to predict survival early after IAT provides evidence for potential advantages of 3D quantitative tumour analysis.

show abstract

Section: Methodsmentioning

confidence: 99%

Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Despite the noninvasive diagnosis of hepatocellular carcinoma (HCC), especially in those high-risk patients with typical enhancement pattern, accurate diagnosis of HCC still remains difficult when typical imaging features are lacking [1, 2]. Unlike Western countries, the incidence of HCC in Asian-Pacific area is mainly based on the chronic hepatitis B virus or hepatitis C virus infection [3, 4].…”

Section: Introductionmentioning

confidence: 99%

A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma

Zheng

Yuan

et al. 2020

Liver Cancer

View full text Add to dashboard Cite

Background: To prospectively establish and validate new diagnostic criterion (DC) for liverspecific contrast agents and further compared the diagnostic sensitivity and specificity with conventional DC. Methods: Institutional Review Board approved and written informed consent were obtained for this prospective study. Two board-certified reviewers established the reference standard as hepatocellular carcinoma (HCC), non-HCC lesions by using marks on all cross-sectional MR images. Another 2 abdominal radiologists independently performed the marked lesion observations using 5 different DCs, including DC-1: arterial phase hyperenhancement (APHE) and portal venous phase washout; DC-2: APHE and hepatobiliary phase (HBP) hypointensity; DC-3: APHE and diffusion-weighted imaging (DWI) hyperintensity; DC-4: HBP hypointensity and DWI hyperintensity; DC-5: HBP hypointensity, DWI hyperintensity and excluded these markedly T2 hyperintensity. Diagnostic performance of sensitivity, specificity, and accuracy for each imaging DC was calculated, per-lesion diagnostic sensitivity and specificity of imaging criteria were compared by using McNemars test. Results: A total of 215 patients were included (mean age 53.82 ± 11.24 years; range 24-82 years) with 265 hepatic nodules (175 HCCs and 90 non-HCCs). The DC-4 (93.71%; 164/175) and DC-5 (92.57%; 162/175) yielded the highest diagnostic sensitivity and was better than DC-1 (72.57%; 127/175), DC-2 (82.86%; 145/175), and DC-3 (82.29%; 144/175) (all p < 0.001). The specificity of DC-1 (94.44%;

show abstract

“…MR imaging also permit assessment of ancillary imaging features, that can be divided into those that favor the diagnosis of HCC specifically (intralesional fat, corona enhancement, nodule-in-nodule architecture, and mosaic architecture) and those that favor the diagnosis of malignancy but are not specific for HCC (mild-moderate T2 hyperintensity, restricted diffusion, and lesional iron sparing) [5–7, 81]. …”

Section: Hypointense Signal On Hepatobiliary Phasementioning

confidence: 99%

“…Therefore American College of Radiology (ACR) sustained the spread of Liver Imaging Reporting and Data System (LI-RADS) to homogenizing the interpreting, reporting and data collection of HCC imaging [6]. LI-RADS is a scheme for interpreting and reporting of imaging features on multidetector computed tomography (CT) and magnetic resonance (MR) studies in patients at risk for hepatocellular carcinoma (HCC) [5–7]. In the current (v. 2014) LI-RADS [6], the diagnosis of HCC is based on the presence of major imaging features.…”

Section: Introductionmentioning

confidence: 99%

Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update

Granata

Fusco

Avallone

et al. 2017

Infect Agents Cancer

View full text Add to dashboard Cite

Liver Imaging Reporting and Data System (LI-RADS) is a system for interpreting and reporting of imaging features on multidetector computed tomography (MDCT) and magnetic resonance (MR) studies in patients at risk for hepatocellular carcinoma (HCC). American College of Radiology (ACR) sustained the spread of LI-RADS to homogenizing the interpreting and reporting data of HCC patients. Diagnosis of HCC is due to the presence of major imaging features. Major features are imaging data used to categorize LI-RADS-3, LI-RADS-4, and LI-RADS-5 and include arterial-phase hyperenhancement, tumor diameter, washout appearance, capsule appearance and threshold growth. Ancillary are features that can be used to modify the LI-RADS classification. Ancillary features supporting malignancy (diffusion restriction, moderate T2 hyperintensity, T1 hypointensity on hapatospecifc phase) can be used to upgrade category by one or more categories, but not beyond LI-RADS-4. Our purpose is reporting an overview and update of major and ancillary MR imaging features in assessment of HCC.

show abstract

Understanding LI-RADS

Cited by 37 publications

References 31 publications

Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver

Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver

A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma

Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update

Contact Info

Product

Resources

About